Men with early-stage prostate cancer may be able to inhibit tumor growth and progression by following a high-fiber diet, according to recent study results. Read the article.
Diet can thwart prostate cancer progression Read More »
New findings add to mounting evidence suggesting that tea consumption may lower the risk of developing prostate cancer. The findings are based on a population-based case-control study conducted in King County, Washington. The study, by Milan S. Geybels, MSc, of the Department of Epidemiology, Maastricht University, Maastricht, The Netherlands, and colleagues examined associations between PCa risk and tea and coffee consumption. The tea-related analysis focused on 863 PCa cases and 863 controls; the coffee-related analysis included 894 cases and 860 controls. Read the article.
Tea May Lower Prostate Cancer Risk Read More »
Evan Y. Yu, MD describes his clinical approach to the treatment patients with bone metastases secondary to prostate cancer. View this video.
Optimizing Therapeutic Strategies Targeting Bone: Prostate Cancer Read More »
Schulich School of Medicine & Dentistry professor Hon Leong has developed a new blood test which could detect the potential for prostate cancer earlier. Thousands of men face a prostate biopsy following higher-than-normal results from their annual prostate-specific antigen (PSA) test, the traditional screening for prostate cancer. But recent studies have shown three in four of these biopsies were unnecessary, leading to 165,000 unnecessary procedures and 6,930 related hospitalizations each year. Read more at: http://medicalxpress.com/news/2013-02-prostate-cancer-treatment.html#jCp
New prostate cancer test could change treatment. Read More »
Abstract Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. The mechanism of CRPC is not fully understood, but it may result from multiple pathways, including a loss or androgen receptor (AR) specificity and increased downstream signalling activity that provide multiple targets for therapeutic agents. For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. In Phase III clinical trials, these agents have
Not surprisingly, a cancer diagnosis creates stress. And patients with prostate cancer show higher levels of anxiety compared to other cancer patients. A new study by researchers at Wake Forest Baptist Medical Center indicates that stress is not just an emotional side effect of the diagnosis; it also can reduce the effectiveness of prostate cancer drugs and accelerate the development of prostate cancer. Read the article.
Emotional Stress Reduces Effectiveness of Prostate Cancer Therapies in Animal Model Read More »
PSA concentrations are higher in men who engage in more sedentary behavior and lower levels of light physical activity, a study found. It is hypothesized that regular participation in physical activity may reduce prostate cancer risk through a variety of biological mechanisms including changes in energy balance, immune function, inflammation, antioxidant defenses, and endogenous hormones. Based on their results, the authors stated, evaluation of a patient’s physical activity and sedentary level before PSA testing also is important because these factors also may influence measurements and lead to a urologic diagnostic workup. Read the whole article.
PSA Levels Higher in Sedentary Men Read More »
Most men with incontinence following RP have normal bladder function; their incontinence is usually due to intrinsic sphincteric urethral deficiency. When urodynamic study confirms this diagnosis and flexible cystoscopy, shows no significant urethral stricture, artificial urinary sphincter implantation is indicated. Read the Article.
Artificial Urinary Sphincter Implantation for Post-RP Urinary Incontinence Read More »
November 2012 Awareness Night “Radiation Therapy for Prostate Cancer in 2012 and beyond.” Dr. Padrick Warde, MD, MCChB BAO, FRCPC Professor, Department of Radiation Oncology, University of Toronto Staff Radiation Oncologist, The Princess Margaret Cancer Centre/University Health Network Associate Director, Radiation Medicine Program, The Princess Margaret Cancer Centre CLICK ON THE ARROW TO START THE VIDEO Complete Presentation “Radiation Therapy for Prostate Cancer in 2012 and beyond.” High Definition 49inutes Click here to return to top. Click here to return to our main “Videos” page.
VIDEO: Dr. Padrick Warde, “Radiation Therapy for Prostate Cancer in 2012 and beyond.” Read More »
Targeted biopsy of suspected prostate cancer (PCa) lesions, identified using magnetic resonance-ultrasound (MR-US) fusion, increases PCa detection and detects aggressive tumors that may be missed by conventional biopsy, according to a study published in The Journal of Urology (2012;189:86-92). Read the Article.
MR-US Fusion Targeted Biopsy Boosts Detection of Prostate Cancer Read More »